Determination of the molar absorption coefficient of fluorescein sodium.
Explore the source record for details and available documents.
Calibration↗
Biomedical subjects
J den Hartigh
Publications and source records attributed to J den Hartigh.
Stability of azacitidine in lactated Ringer's injection frozen in polypropylene syringes.
The stability of azacitidine diluted in lactated Ringer's injection was studied. Azacitidine was reconstituted with ice-cold lactated Ringer's injection to concentrations of 2.0 and 0.5 mg/mL and stored in polypropylene syringes at -20 degrees C. On days 1, 3, 7, and 14, the solutions were thawed over 30-45 minutes and the azacitidine concentration was determined by high-performance liquid chromatography immediately after thawing and one, three, and six hours later. Other studies were conducted at 37, 20, and 0-4 degrees C to determine decomposition rate constants for azacitidine at both concentrations. Hydrolysis of azacitidine resulted in a biphasic decline when the log of the percentage of drug remaining was plotted against time. No substantial decomposition occurred during storage at -20 degrees C. In thawed samples, azacitidine concentrations decreased to 90% of the initial concentrations within three hours after reaching room temperature; similar decreases in concentration were seen in nonfrozen samples stored at room temperature. The results of these studies indicate that azacitidine solutions in lactated Ringer's injection can be stored in polypropylene syringes at -20 degrees C for two weeks without decomposition. The thawed solutions should be used within three hours.
Azacitidine↗
Relationship between clinical parameters and pharmacokinetics of mitomycin C.
Although the number of reports on mitomycin C (MMC) pharmacokinetics is increasing, data on possible relations between clinical parameters and pharmacokinetics are usually lacking. The present report concerns the results of a detailed study on this subject in 35 patients receiving MMC, either as a single agent or as a part of combination chemotherapy. MMC concentrations were determined by HPLC. T1/2 beta varied from 23 to 78 min, VD from 11 to 48 l/m2, Cl tot from 12 to 42 l/h per m2, and AUC from 138 to 1221 micrograms/h per l, confirming previously reported data. Infusion time, cholestasis, and urinary pH did not influence the pharmacokinetic data. There were no relations between other clinical data and pharmacokinetics, nor between AUC and bone marrow toxicity. An interaction between MMC and furosemide could not be excluded, but there was no interaction with other comedication. Consecutive pharmacokinetics in 6 patients showed consistent results. Because renal impairment does not alter MMC pharmacokinetics and renal excretion is not a major route of elimination, it is suggested that renal impairment does not call for dose adjustment.
Adult↗